Search results
Showing 16 to 30 of 110 results for dexamethasone
Evidence-based recommendations on belantamab mafodotin (Blenrep) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when a stem cell transplant is unsuitable.
NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma. This is because Janssen did not provide an evidence submission.
Show all sections
Sections for TA634
NICE is unable to make a recommendation on lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma in adults. This is because Celgene did not provide an evidence submission.
Show all sections
Sections for TA603
NICE is unable to make a recommendation on isatuximab (Sarclisa) with carfilzomib (Kyprolis) and dexamethasone for treating relapsed or refractory multiple myeloma because Sanofi did not provide an evidence submission.
Show all sections
Sections for TA727
NICE is unable to make a recommendation on daratumumab (Darzalex) with pomalidomide (Imnovid) and dexamethasone for treating relapsed or refractory multiple myeloma because Janssen did not provide an evidence submission.
Show all sections
Sections for TA726
NICE is unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA841
NICE is unable to make a recommendation on pomalidomide (Imnovid) with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Celgene did not provide an evidence submission.
Show all sections
Sections for TA602
NICE is unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma because no evidence submission was received from Janssen-Cilag.
Show all sections
Sections for TA454
In development Reference number: GID-TA11254 Expected publication date: 06 August 2026
Awaiting development Reference number: GID-TA10198 Expected publication date: TBC
Awaiting development Reference number: GID-TA11660 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.
In development Reference number: GID-TA11660 Expected publication date: TBC